Intracellular “smoke detector” discovery has skin disease therapy implications
A study by the University of Bonn in Germany could lead to therapies against skin…
March 23, 2023 - 3 minutes
Skin disease
Dupixent gets EU nod for children with severe atopic dermatitis
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive…
January 27, 2023 - 4 minutes
Aditxt forms Adimune to focus on immune modulation therapies
Aditxt, Inc., a biotech innovation company developing and commercializing technologies with a focus on monitoring…
January 4, 2023 - 3 minutes
European Commission approves Dupixent as first and only targeted prurigo nodularis medicine
The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European…
December 15, 2022 - 5 minutes
TrialSpark acquires immunodermatology portfolio and creates Libertas Bio
TrialSpark has announced the formation of Libertas Bio following the acquisition of a majority position…
November 30, 2022 - 3 minutes
New Replay HSV gene therapy company Telaria to focus on skin diseases
Replay has announced the launch of Telaria, a herpes simplex virus (HSV) gene therapy company…
November 21, 2022 - 3 minutes
A new treatment for tackling epidermolysis bullosa
By Jordi Casals, president, EMEA, Amryt Pharma Epidermolysis bullosa (EB), sometimes described as “the worst…
November 14, 2022 - 3 minutes
Prurigo nodularis treatment recommended for EU approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a…
November 11, 2022 - 3 minutes
Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo
Incyte has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded…
October 3, 2022 - 3 minutes
Treatment for adults with chronic skin condition approved by FDA
The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of…
September 29, 2022 - 4 minutes
Kamari Pharma raises $8M in investment for development of drugs for skin diseases
An $8 million investment has been raised by Kamari Pharma following investment from the Guangzhou-Israel…
September 19, 2022 - 3 minutes
Regeneron and Sanofi announce published trial results in children with dermatitis
Positive results from a phase 3 trial in children aged 6 months to five years…
September 16, 2022 - 3 minutes
